ADC Therapeutics SA (ADCT) Appoints Jean-Pierre Bizzari to its Board

ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of veteran oncology drug developer Jean-Pierre Bizzari, MD, to its Board of Directors. Additionally, Ameet Mallik, who was appointed as the Company’s Chief Executive Officer in May 2022, will join the Board.

“Jean-Pierre is an exceptional addition to our Board,” said Ron Squarer, Chairman of ADC Therapeutics’ Board of Directors. “His integral role in the development and approval of leading cancer treatments across global markets will bring valuable perspective to ADC Therapeutics as we advance a robust pipeline of ADCs for the treatment of hematological cancers and solid tumors.”

Dr. Jean-Pierre Bizzari is an internationally renowned oncologist with over 35 years of experience in oncology drug development. He was Executive Vice President and Group Head of Clinical Oncology Development at Celgene Corporation where he was responsible for clinical development and operations across the United States, Europe and Asia/Japan. During his tenure at Celgene, he oversaw the development and approval of leading oncology products including REVLIMID® (lenalidomide), VIDAZA® (azacytidine), and ABRAXANE® (nab-paclitaxel). Dr. Bizzari also served as Vice President, Clinical Oncology Development for Sanofi-Aventis (formerly Rhône-Poulenc, Rhône-Poulenc Rorer and Aventis) where he oversaw the approval of ELOXATIN® (oxaliplatin), TAXOTERE® (docetaxel) and ELITEK® (rasburicase).

Dr. Bizzari currently serves on the scientific advisory boards of France’s National Cancer Institute and the European Organisation for Research and Treatment of Cancer. He also serves on the scientific advisory boards and board of directors at numerous global pharmaceutical companies. Dr. Bizzari has received various industry honors and has authored hundreds of scientific articles and publications.

Dr. Bizzari received his medical degree from the University of Nice and has trained at the Pitié-Salpêtrière Hospital in Paris, the Ontario Institute for Cancer Research, and the McGill Rosalind and Morris Goodman Cancer Research Centre (formerly the McGill Cancer Center) in Montreal, Canada.

“With a proprietary ADC platform validated by the FDA approval of ZYNLONTA®, a robust pipeline of solid tumor targets and a global team committed to transforming patients’ lives, ADC Therapeutics is poised to build on its success,” said Dr. Bizzari. “I look forward to working with the Board to continue ADC Therapeutics’ positive momentum and make a meaningful difference for patients with difficult-to-treat cancers.”

You May Also Be Interested In

• 22nd Century Group (XXII) Announces Resignation of Sullivan and Mish from Board
• Vertex Pharma (VRTX) Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
• 22nd Century Group (XXII) Regains Nasdaq Compliance